Mayne Pharma Group Limited

Symbol: MYX.AX

ASX

6.8

AUD

Market price today

  • -2.3865

    P/E Ratio

  • -0.0091

    PEG Ratio

  • 578.51M

    MRK Cap

  • 0.00%

    DIV Yield

Mayne Pharma Group Limited (MYX-AX) Stock Price & Analysis

Shares Outstanding

85.07M

Gross Profit Margin

0.44%

Operating Profit Margin

-0.38%

Net Profit Margin

-0.90%

Return on Assets

-0.21%

Return on Equity

-0.41%

Return on Capital Employed

-0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Shawn Patrick O'Brien B.Sc
Full-time employees:850
City:Salisbury South
Address:1538 Main North Road
IPO:2007-06-29
CIK:

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

General Outlook

In simple terms, Mayne Pharma Group Limited has 85.074 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.437% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.381%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.897%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.210% return, is a testament to Mayne Pharma Group Limited's adeptness in optimizing resource deployment. Mayne Pharma Group Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.410%. Furthermore, the proficiency of Mayne Pharma Group Limited in capital utilization is underscored by a remarkable -0.120% return on capital employed.

Stock Prices

Mayne Pharma Group Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.9, while its low point bottomed out at $6.76. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Mayne Pharma Group Limited's stock market.

Liquidity Ratios

Analyzing MYX.AX liquidity ratios reveals its financial health of the firm. The current ratio of 160.76% gauges short-term asset coverage for liabilities. The quick ratio (104.20%) assesses immediate liquidity, while the cash ratio (36.94%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio160.76%
Quick Ratio104.20%
Cash Ratio36.94%

Profitability Ratios

MYX.AX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -65.85% underscores its earnings before tax deductions. The effective tax rate stands at -45.38%, revealing its tax efficiency. The net income per EBT, 136.16%, and the EBT per EBIT, 172.81%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -38.11%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-65.85%
Effective Tax Rate-45.38%
Net Income per EBT136.16%
EBT per EBIT172.81%
EBIT per Revenue-38.11%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.61, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding104
Days of Inventory Outstanding220
Operating Cycle488.71
Days of Payables Outstanding102
Cash Conversion Cycle386
Receivables Turnover1.36
Payables Turnover3.56
Inventory Turnover1.66
Fixed Asset Turnover5.37
Asset Turnover0.23

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.12, and free cash flow per share, -0.36, depict cash generation on a per-share basis. The cash per share value, 1.34, showcases liquidity position. A payout ratio of -0.19 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.12
Free Cash Flow per Share-0.36
Cash per Share1.34
Payout Ratio-0.19
Operating Cash Flow Sales Ratio-0.04
Free Cash Flow to Operating Cash Flow Ratio3.01
Cash Flow Coverage Ratio-0.29
Short Term Coverage Ratio-2.79
Capital Expenditure Coverage Ratio-0.50
Dividend Paid and Capex Coverage Ratio-0.15
Dividend Payout Ratio0.12

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.90%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.20%, and total debt to capitalization, 5.76%, ratios shed light on its capital structure. An interest coverage of -17.50 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.90%
Debt Equity Ratio0.06
Long Term Debt to Capitalization5.20%
Total Debt to Capitalization5.76%
Interest Coverage-17.50
Cash Flow to Debt Ratio-0.29
Company Equity Multiplier2.11

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.13, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.67, reflects the portion of profit attributed to each share. The book value per share, 7.35, represents the net asset value distributed per share, while the tangible book value per share, 0.20, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.13
Net Income Per Share-3.67
Book Value Per Share7.35
Tangible Book Value Per Share0.20
Shareholders Equity Per Share7.35
Interest Debt Per Share0.62
Capex Per Share-2.55

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 5.89%, indicates top-line expansion, while the gross profit growth, -12.63%, reveals profitability trends. EBIT growth, 55.42%, and operating income growth, 55.42%, offer insights into operational profitability progression. The net income growth, -31.03%, showcases bottom-line expansion, and the EPS growth, -25.19%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth5.89%
Gross Profit Growth-12.63%
EBIT Growth55.42%
Operating Income Growth55.42%
Net Income Growth-31.03%
EPS Growth-25.19%
EPS Diluted Growth-25.19%
Weighted Average Shares Growth4.74%
Weighted Average Shares Diluted Growth4.74%
Operating Cash Flow Growth-427.66%
Free Cash Flow Growth-706.31%
10-Year Revenue Growth per Share37.91%
5-Year Revenue Growth per Share-28.80%
3-Year Revenue Growth per Share-27.49%
10-Year Operating CF Growth per Share-854.04%
5-Year Operating CF Growth per Share-44.84%
3-Year Operating CF Growth per Share-262.14%
10-Year Net Income Growth per Share-2478.68%
5-Year Net Income Growth per Share-81.72%
3-Year Net Income Growth per Share13.48%
10-Year Shareholders Equity Growth per Share25.02%
5-Year Shareholders Equity Growth per Share-59.07%
3-Year Shareholders Equity Growth per Share-49.78%
10-Year Dividend per Share Growth per Share-73.47%
Receivables Growth46.35%
Inventory Growth6.24%
Asset Growth-11.98%
Book Value per Share Growth-29.82%
Debt Growth19.27%
R&D Expense Growth-22.47%
SGA Expenses Growth-12.04%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 325,339,400, captures the company's total value, considering both debt and equity. Income quality, 0.14, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.32, gauges operational efficiency, while the research and development to revenue, 8.57%, highlights investment in innovation. The ratio of intangibles to total assets, 49.45%, indicates the value of non-physical assets, and capex to operating cash flow, 509.21%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value325,339,400
Income Quality0.14
Sales General and Administrative to Revenue0.32
Research and Development to Revenue8.57%
Intangibles to Total Assets49.45%
Capex to Operating Cash Flow509.21%
Capex to Revenue-119.61%
Capex to Depreciation-335.55%
Stock-Based Compensation to Revenue3.69%
Graham Number24.64
Return on Tangible Assets-50.16%
Graham Net Net-2.16
Working Capital242,670,000
Tangible Asset Value17,096,000
Net Current Asset Value-60,145,000
Average Receivables246,268,000
Average Payables47,799,000
Average Inventory95,804,000
Days Sales Outstanding417
Days Payables Outstanding75
Days of Inventory On Hand193
ROIC-32.18%
ROE-0.50%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.06, and the price to book ratio, 1.06, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.24, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -20.79, and price to operating cash flows, -59.72, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.06
Price to Book Ratio1.06
Price to Sales Ratio2.24
Price Cash Flow Ratio-59.72
Price Earnings to Growth Ratio-0.01
Enterprise Value Multiple-21.98
Price Fair Value1.06
Price to Operating Cash Flow Ratio-59.72
Price to Free Cash Flows Ratio-20.79
Price to Tangible Book Ratio0.60
Enterprise Value to Sales1.77
Enterprise Value Over EBITDA-2.69
EV to Operating Cash Flow-7.54
Earnings Yield-83.37%
Free Cash Flow Yield-69.22%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Mayne Pharma Group Limited (MYX.AX) on the ASX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.386 in 2024.

What is the ticker symbol of Mayne Pharma Group Limited stock?

The ticker symbol of Mayne Pharma Group Limited stock is MYX.AX.

What is company IPO date?

IPO date of Mayne Pharma Group Limited is 2007-06-29.

What is company current share price?

Current share price is 6.800 AUD.

What is stock market cap today?

The market cap of stock today is 578505267.000.

What is PEG ratio in 2024?

The current -0.009 is -0.009 in 2024.

What is the number of employees in 2024?

In 2024 the company has 850.